The Team

  • Researchers

    Hinrich GRONEMEYER

  • Engineers & Technicians

    Cathie ERB

Research

Functional genomics and cancer

Systems biology of cell fate decisions in normal and tumor cells

Our interest is to understand the mechanisms and dynamics of signal transduction, epigenetic (de)regulation and chromatin structure, which coordinate global gene expression programs in normal and cancer cells. Based on our expertise on nuclear receptors action we develop technologies and global systems biology approaches to identify comprehensive RNA profiles, transcription factor binding sites, epigenomes and chromatin interactomes from ultra-small sample sizes, and use integrative bioinformatics to identify functional gene “hubs” and decision points that dynamically coordinate gene programming. Our studies involve a plethora of genome-wide technologies and the corresponding development of bioinformatics tools.

 

A particular interest of our team is the integrative analysis of aberrations affecting signaling, epigenome, chromatin architecture and transcriptome upon tumorigenic transformation. In this context we identify targets and mechanisms, which are relevant for the development of novel therapeutic paradigms, and study the mechanisms and therapeutic potential of signaling drugs and epigenetic modulators.

 

Another emphasis of our work is to decipher the mechanisms underlying the cancer-selectivity of apoptogenic TRAIL signaling. Studies on the role of the senescence-mediated secretome on TRAIL action and the epigenetic alterations during cellular senescence address the link between cancer and aging.

Team website

  • Current projects

    - Study of the molecular mechanisms controlling the modulation of TRAIL-dependent signaling by non-muscle myosins.
    - Deciphering the molecular Mechanisms Underlying the modulation of TRAIL-induced signaling by non-muscular myosins. AICR
    - Characterization of a novel epigenetic putative regulator of gene expression in breast cancer. Project funded by INCa.
    - Analysis Of interactions between ndsRNAs recently discovered, and the factors / complex epigenetic during tumorigenesis. Project EpiCaR (Epigenetics, Cancer and ndsRNAs) funded by the Cancer Plan.
    - Identification of modulators and gene expression signatures of TRAIL sensitivity. Project funded by ARC
    - Epigenetic regulation of tumour-cell specific apoptosis. Project financed by the INCa

  • Collaborations

    - Dr. Peter MULLIGAN, Centre de Recherche en Cancérologie de Lyon (CRCL), UMR Inserm 1052 CNRS 5286 Centre Léon Bérard.
    - Dr. Laurence Vandel, Centre de Biologie du Developpement, UMR5547 du CNRS/Universite Paul Sabatier, Toulouse, FRANCE

  • Prizes/Awards

    • Hinrich GRONEMEYER - René & Andrée Duquesne prize - Ligue contre le cancer - 2015
    • Hinrich GRONEMEYER - Scientific Excellence Award - Inserm - 2010
    • Hinrich GRONEMEYER - European Medal - The Endocrine Society - 1996
    • Hinrich GRONEMEYER - Member of the European Molecular Biology Organization (EMBO) - European Molecular Biology Organization (EMBO) - 1995
    • Hinrich GRONEMEYER - Scientific Prize - Société Française d'Endocrinologie (SFE) - 1991

  • News

  • Publications

    • Promising strategies: Combination of epigenetic inhibitors for cancer therapy.

      Gronemeyer H

      Int J Cancer Nov. 15, 2020 ; 147:2656-2657 .

    • A comprehensive resource for retrieving, visualizing, and integrating functional genomics data.

      Blum M, Cholley PE, Malysheva V, Nicaise S, Moehlin J, Gronemeyer H, Mendoza-Parra MA

      Life Sci Alliance Jan 2020 ; 3: .

    • Inference from RNA interference: Suggestions to our authors.

      Gronemeyer H

      Int J Cancer Jan. 1, 2020 ; 146:9 .

    • Activation of the Endonuclease that Defines mRNA 3' Ends Requires Incorporation into an 8-Subunit Core Cleavage and Polyadenylation Factor Complex.

      Hill CH(1), Boreikaite V(1), Kumar A(1), Casanal A(1), Kubik P(1), Degliesposti G(1), Maslen S(1), Mariani A(1), von Loeffelholz O(2), Girbig M(1), Skehel M(1), Passmore LA(3).

      Mol Cell March 21, 2019 ; 73:1217-1231 .

    • CBP and P300 regulate distinct gene networks required for human primary myoblast differentiation and muscle integrity.

      Fauquier L(1), Azzag K(1)(2), Parra MAM(3), Quillien A(1), Boulet M(1)(4), Diouf S(1)(4), Carnac G(5), Waltzer L(1)(4), Gronemeyer H(3), Vandel L(6)(7).

      Sci Rep Aug. 22, 2018 ; 8:12629 .

    • Modeling gene-regulatory networks to describe cell fate transitions and predict master regulators.

      Cholley PE(1)(2), Moehlin J(1), Rohmer A(1), Zilliox V(1), Nicaise S(1), Gronemeyer H(1), Mendoza-Parra MA(1)(3).

      NPJ Syst Biol Appl Aug. 2, 2018 ; 4:29 .

    • Development of biotin-retinoid conjugates as chemical probes for analysis of retinoid function.

      Fujii S(1), Mori S(2), Kagechika H(2), Mendoza Parra MA(3), Gronemeyer H(4).

      Bioorg Med Chem Lett Aug. 1, 2018 ; 28:2442-2445 .

    • Daughter-cell-specific modulation of nuclear pore complexes controls cell cycle entry during asymmetric division.

      Kumar A(1)(2), Sharma P(1)(2), Gomar-Alba M(3)(4)(5)(6), Shcheprova Z(1)(2), Daulny A(1)(2), Sanmartin T(1)(2), Matucci I(1)(2), Funaya C(7), Beato M(1)(2), Mendoza M(8)(9)(10)(11)(12)(13).

      Nat Cell Biol Apr 2018 ; 20:432-442 .

    • Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

      Galluzzi L(1)(2)(3), Vitale I(4)(5), Aaronson SA(6), Abrams JM(7), Adam D(8), Agostinis P(9), Alnemri ES(10), Altucci L(11), Amelio I(12), Andrews DW(13)(14)(15), Annicchiarico-Petruzzelli M(16), Antonov AV(12), Arama E(17), Baehrecke EH(18), Barlev NA(19), Bazan NG(20), Bernassola F(21), Bertrand MJM(22)(23), Bianchi K(24), Blagosklonny MV(25), Blomgren K(26)(27), Borner C(28)(29), Boya P(30), Brenner C(31)(32), Campanella M(4)(5)(33)(34), Candi E(16)(21), Carmona-Gutierrez D(35), Cecconi F(4)(36)(37), Chan FK(38), Chandel NS(39), Cheng EH(40), Chipuk JE(6), Cidlowski JA(41), Ciechanover A(42), Cohen GM(43), Conrad M(44), Cubillos-Ruiz JR(45)(46), Czabotar PE(47)(48), D'Angiolella V(49), Dawson TM(50)(51)(52)(53), Dawson VL(50)(51)(53)(54), De Laurenzi V(55), De Maria R(56), Debatin KM(57), DeBerardinis RJ(58), Deshmukh M(59), Di Daniele N(60), Di Virgilio F(61), Dixit VM(62), Dixon SJ(63), Duckett CS(64), Dynlacht BD(65)(66), El-Deiry WS(67)(68), Elrod JW(69), Fimia GM(70)(71), Fulda S(72)(73)(74), Garcia-Saez AJ(75), Garg AD(9), Garrido C(76)(77)(78), Gavathiotis E(79)(80)(81)(82), Golstein P(83), Gottlieb E(42)(84), Green DR(85), Greene LA(86), Gronemeyer H(87)(88)(89)(90), Gross A(91), Hajnoczky G(92), Hardwick JM(93), Harris IS(94), Hengartner MO(95), Hetz C(96)(97)(98), Ichijo H(99), Jaattela M(100), Joseph B(101), Jost PJ(102), Juin PP(103)(104)(105)(106), Kaiser WJ(107), Karin M(108)(109)(110)(111), Kaufmann T(112), Kepp O(113)(114)(115)(116)(117)(118), Kimchi A(17), Kitsis RN(80)(81)(82)(119)(120), Klionsky DJ(121)(122), Knight RA(12), Kumar S(123), Lee SW(124), Lemasters JJ(125)(126), Levine B(127)(128)(129), Linkermann A(130), Lipton SA(131)(132)(133), Lockshin RA(134)(135), Lopez-Otin C(136), Lowe SW(137)(138), Luedde T(139), Lugli E(140)(141), MacFarlane M(12), Madeo F(35)(142), Malewicz M(12), Malorni W(143), Manic G(4)(5), Marine JC(144)(145), Martin SJ(146), Martinou JC(147), Medema JP(148)(149), Mehlen P(150)(151)(152)(153)(154)(155), Meier P(156), Melino S(157), Miao EA(158)(159)(160), Molkentin JD(161), Moll UM(162), Munoz-Pinedo C(163), Nagata S(164), Nunez G(165)(166), Oberst A(167)(168), Oren M(169), Overholtzer M(170), Pagano M(66)(171)(172), Panaretakis T(173)(174), Pasparakis M(175)(176), Penninger JM(177), Pereira DM(178), Pervaiz S(179)(180)(181), Peter ME(182)(183), Piacentini M(4)(70), Pinton P(61)(184)(185), Prehn JHM(186), Puthalakath H(187), Rabinovich GA(188)(189), Rehm M(190)(191), Rizzuto R(192), Rodrigues CMP(193), Rubinsztein DC(194), Rudel T(195), Ryan KM(84), Sayan E(196), Scorrano L(197)(198), Shao F(199), Shi Y(200)(201)(202), Silke J(48)(203), Simon HU(112), Sistigu A(56)(204), Stockwell BR(205)(206), Strasser A(47), Szabadkai G(192)(207)(208), Tait SWG(84), Tang D(209)(210)(211)(212)(213)(214), Tavernarakis N(215), Thorburn A(216), Tsujimoto Y(217), Turk B(218)(219), Vanden Berghe T(22)(23), Vandenabeele P(22)(23), Vander Heiden MG(220)(221)(222), Villunger A(223), Virgin HW(224), Vousden KH(208), Vucic D(225), Wagner EF(226), Walczak H(227), Wallach D(228), Wang Y(229), Wells JA(230), Wood W(231), Yuan J(94)(232), Zakeri Z(233), Zhivotovsky B(101)(234), Zitvogel L(114)(235)(236)(237), Melino G(12)(21), Kroemer G(238)(239)(240)(241)(242)(243)(244).

      Cell Death Differ Jan. 23, 2018 ; 25:486-541 .

    • Senescence-associated reprogramming promotes cancer stemness.

      Milanovic M(1), Fan DNY(1)(2)(3)(4), Belenki D(1), Dabritz JHM(1), Zhao Z(5), Yu Y(6), Dorr JR(1), Dimitrova L(7), Lenze D(7), Monteiro Barbosa IA(8), Mendoza-Parra MA(9), Kanashova T(6), Metzner M(1), Pardon K(1), Reimann M(1), Trumpp A(2)(3)(4)(10), Dorken B(1)(2)(4)(6)(11), Zuber J(8), Gronemeyer H(9), Hummel M(2)(4)(7)(11), Dittmar G(6)(12), Lee S(1)(2)(4)(6), Schmitt CA(1)(2)(4)(6)(11).

      Nature Jan. 4, 2018 ; 553:96-100 .

    See all publications=>

  • Job opportunities

  • Alumni

  • Videos

  • Thesis subjects

Imprimer Envoyer

IGBMC
Research
Technologies
Training
Events
Infrastructures
Université de Strasbourg
INSERM
CNRS


© IGBMC 2012 - Legal mentions

IGBMC - CNRS UMR 7104 - Inserm U 1258
1 rue Laurent Fries / BP 10142 / 67404 Illkirch CEDEX / France Tél +33 (0)3 88 65 32 00 / Fax +33 (0)3 88 65 32 01 / directeur.igbmc@igbmc.fr